147118-39-6

Basic information

• Product Name: Methyl(+)-(3-R)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesul fonylamino) pyrimidin-5-yl]-3-hydroxy-5-oxo-6(E)-heptenoate
• Synonyms: Methyl(+)-(3-R)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesul fonylamino) pyrimidin-5-yl]-3-hydroxy-5-oxo-6(E)-heptenoate;ZD-6 ;(3R,6E)-7-[4-(4-Fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3-hydroxy-5-oxo-6-heptenoic acid methyl ester;Methyl 7-[4-(4-FLUOROPHENYL)-6-ISO-PROPYL-2-(N-METHYL-N-METHYLSULFONYLAMINO)PYRIMIDIN-5-YL] -(3R,5R)-DIHYDROXY-(E)-6-HEPTENATE;Methyl(+)-(3-R)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-(N-Methyl-N-Methanesul fonylaMino) pyriMidin-5-y;(R,E)-Methyl 7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-MethylMethylsulfonaMido)pyriMidin-5-yl)-3-hydroxy-5-oxohept-6-enoate;Methyl (+)-(3R)-7-[4-(4-fluorophenyl)- 6-isopropyl-2-(N-Methyl-NMethansulphonylaMino) pyriMidin-5-yl]-3-hydroxy-5-oxo- 6(E)-heptenoate;5-Oxorosuvastatin Methyl ester
• CAS NO: 147118-39-6
• Molecular Formula: C₂₃H₂₈FN₃O₆S
• Molecular Weight: 493.55
• EINECS: 1312995-182-4
• Mol File: 147118-39-6.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 701.68 °C at 760 mmHg
• Flash Point: 378.163 °C
• Appearance: /
• Density: 1.311
• Vapor Pressure: 1.15E-20mmHg at 25°C
• Refractive Index: 1.569
• Storage Temp.: 2-8°C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 12.87±0.20(Predicted)
• CAS DataBase Reference: Methyl(+)-(3-R)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesul fonylamino) pyrimidin-5-yl]-3-hydroxy-5-oxo-6(E)-heptenoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl(+)-(3-R)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesul fonylamino) pyrimidin-5-yl]-3-hydroxy-5-oxo-6(E)-heptenoate(147118-39-6)
• EPA Substance Registry System: Methyl(+)-(3-R)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesul fonylamino) pyrimidin-5-yl]-3-hydroxy-5-oxo-6(E)-heptenoate(147118-39-6)

Safety Data

• Hazardous Substances Data: 147118-39-6(Hazardous Substances Data)

Usage

Description

Methyl(+)-(3-R)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesulfonylamino) pyrimidin-5-yl]-3-hydroxy-5-oxo-6(E)-heptenoate is a complex organic compound with a unique chemical structure. It is characterized by its fluorophenyl and isopropyl groups, as well as its N-methyl-N-methanesulfonylamino functional group. This molecule is likely to have specific interactions with biological targets due to its distinct structural features.

Uses

1. Used in Pharmaceutical Industry:
Methyl(+)-(3-R)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesulfonylamino) pyrimidin-5-yl]-3-hydroxy-5-oxo-6(E)-heptenoate is used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows it to be a key component in the development of new drugs with potential therapeutic applications.
2. Used in Synthesis of Rosuvasatatin:
Methyl(+)-(3-R)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesulfonylamino) pyrimidin-5-yl]-3-hydroxy-5-oxo-6(E)-heptenoate is used as an intermediate in the synthesis of Rosuvasatatin (calcium salt: R700500), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. Methyl(+)-(3-R)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesul
fonylamino) pyrimidin-5-yl]-3-hydroxy-5-oxo-6(E)-heptenoate is effective in decreasing high-sensitivity C-reactive protein (hsCRP) and cholesterol concentrations in the blood, making it a valuable component in the treatment of cardiovascular diseases.
3. Used in Drug Delivery Systems:
The compound may also be utilized in the development of drug delivery systems, where its unique structural features can be exploited to improve the targeting, bioavailability, and therapeutic efficacy of various drugs. This application could be particularly relevant in the fields of cancer therapy and other diseases where precise drug targeting is crucial for effective treatment.

InChI:InChI=1/C23H28FN3O6S/c1-14(2)21-19(11-10-17(28)12-18(29)13-20(30)33-4)22(15-6-8-16(24)9-7-15)26-23(25-21)27(3)34(5,31)32/h6-11,14,18,29H,12-13H2,1-5H3/b11-10+/t18-/m1/s1

Upstream product

• 131466-61-0 (3R)-3-<(tert-Butyldimethylsilyl)oxy>pentanedioic acid 1-<(R)-mandelic acid> ester 
• 1350364-18-9 C₁₅H₂₈O₇Si 
• 1350364-00-9 hydrogen (3R)-1-methyl 3-[(tert-butyldimethylsilyl)-oxy]pentanedioate cyclohexylamine salt 
• 147118-35-2 methyl (3R)-3-(tert-butyldimethylsilyloxy)-5-oxo-6-triphenylphosphoranylidenehexanoate 
• 147118-37-4 N-[4-(4-fluorophenyl)-5-formyl-6-isopropylpyrimidin-2-yl]-N-methylmethanesulfonamide 
• 109744-49-2 Hydrogen (3R)-1-methyl 3-<(tert-butyldimethylsilyl)oxy>pentanedioate 
• 91424-40-7 3-(tert-butyldimethylsilyloxy)glutaric anhydride 
• 7664-39-3 hydrogen fluoride 
• 147118-38-5 7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesulfonamido)-pyrimidin-5-yl)-(3R)-3-tert-butyldimethylsiloxy-5-oxo-(E)-6-heptenoic acid methyl ester 
• 147118-30-7 ethyl 2-(N-methyl-N-methanesulfonylamino)-4-(4-fluorophenyl)-6-isopropyl-pyrimidin-5-carboxylic acid 
• 147118-28-3 ethyl 4-(4-fluorophenyl)-6-isopropyl-2-(methylsulfonyl)pyrimidine-5-carboxylate 
• 147118-36-3 N-[4-(4-fluorophenyl)-5-(hydroxymethyl)-6-(propan-2-yl)pyrimidin-2-yl]-N-methylmethanesulfonamide 
• 147118-27-2 ethyl 4-(4-fluorophenyl)-2-(methylsulfanyl)-6-(propan-2-yl)-pyrimidine-5-carboxylate 
• 147118-32-9 5-ethoxycarbonyl-6-(4'-fluorophenyl)-4-isopropyl-2-(methylamino)pyrimidine 

Downstream Products

• 1416820-70-6 rosuvastatin 1-naphthalen-1-yl-ethylamine salt 
• 1416820-71-7 rosuvastatin (R)-1-(1-naphthyl)ethylamine 
• 1197348-98-3 3-methylbutyl (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate 
• 852820-97-4 (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(isopropyl)pyrimidine-5-yl]-3,5-dihydroxyhept-6-enoic acid isopropylamine 
• 1422619-13-3 7-[4-(4-fluorophenyl)-6-isopropyl-2(N-methyl-N-methanesulfonamido)pyrimidin-5-yl]-(3R)-3-hydroxy-5-carbonyl-6-(E)-heptenoic acid 
• 917805-74-4 (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid-2-methylpropan-2-amine 
• 1374771-96-6 rosuvastatin, S-benzylisothiourea salt 
• 287714-41-4 rosuvastatin 
• 147118-40-9 (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid methyl ester 

Relevant articles and documents

Preparation process of rosuvastatin calcium preparation

The invention provides a preparation process of a rosuvastatin calcium preparation, and belongs to the technical field of pharmaceutical preparations. With (3R)-tert-butyldimethylsiloxy-5-oxy-6-triphenylphosphoranylidene methyl caproate and 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonyl amino)pyridine-5-formaldehyde as initial raw materials, wittig reaction, deprotection reaction, chiral reduction reaction, hydrolysis reaction and purification are carried out so as to obtain a rosuvastatin calcium crude drug; then the rosuvastatin calcium crude drug is uniformly mixed with a diluent, a disintegrating agent, a stabilizing agent and a lubricant so as to obtain a mixture, and then the mixture is tabletted so as to obtain the rosuvastatin calcium preparation. The preparation process of the rosuvastatin calcium preparation disclosed by the invention has the advantages of simple operation, high yield, low cost and stable quality.

Preparing rosuvastatin calcium intermediates

The application provides a preparation method for a rosuvastatin calcium intermediate. The method comprises the following steps: a, condensation reaction: a step of adding a main chain Z8 and a side chain J6 into a mixed solution of toluene and acetonitrile, then adding 4-butylammonium bromide, carrying out heating and pressure-reduced concentration so as to obtain a crude H1 product; b, purification of a condensation product: a step of adding a mixture of n-hexane and petroleum ether, and carrying out heating, cooling, heating, filtering and pressure-reduced distillation so as to obtain a H1 product; c, deprotection reaction: a step of adding the H1 product into acetonitrile, then adding an acid-acetonitrile solution under ice bath, after completion of the reaction, controlling a pH value to 7 to 9, then separating the obtained solution and washing an organic layer, further separating the solution and adding a drying agent into the organic layer, then carrying out filtering and pressure-reduced concentration so as to obtain an oily substance, and adding tetrahydrofuran for crystallization so as to obtain an crude H2 product; and d, purification of a deprotection product: a step of adding acetone and tetrahydrofuran, after dissolving, adding activated carbon, and carrying out stirring, hot filtration, cooling, crystallization, filtering and vacuum drying so as to obtain a final H2 product. By using the preparation method for the rosuvastatin calcium intermediate provided by the invention, yield and purity are high, and cost is low.

PROCESS FOR THE PREPARATION OF ROSUVASTATIN CALCIUM VIA NOVEL AMINE INTERMEDIATE

The present invention, relates to novel amine salts of rosuvastatin and its process for the preparation. Moreover, the present invention also relates to improved process for the preparation of rosuvastatin calcium, employing novel amine salts as an intermediate.